ArticleScientific reports2025
Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the short-term treatment outcomes of 80% dose photodynamic therapy (PDT) combined with intravitreal aflibercept injection (IVA) for symptomatic pachychoroid neovasculopathy (PNV) in a working-age population. We retrospectively reviewed a total of 137 eyes of 128 patients (108 males and 20 females) with PNV who were treated with combination therapy. All patients were working-age individuals, and the mean age was 49.0 ± 7.3 (range 33-65) years. Reduced-PDT (80% dose) was performed within 1 week of IVA. The presence of subretinal fluid (SRF) at 1 month and changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and fundus autofluorescence findings were assessed between at baseline and 1 month. One month after the combination therapy, SRF was resolved in 128 eyes (93.4%). The median (interquartile range) BCVA was 0.0 (- 0.08, 0.10)/- 0.08 (- 0.18, 0.05) (p < 0.001), the mean CRT was 374 ± 112/221 ± 36 (p < 0.001), and the mean SFCT was 416 ± 89/371 ± 92 (p < 0.001) at baseline and 1 month, respectively. Hypoautofluorescence, indicating macular atrophy was observed in 1 eye, and 1 eye developed transient visual loss at posttreatment. In terms of the rapid resolution of SRF and the improvement in VA, reduced-PDT combined with IVA can be a treatment option for PNV in the working-age population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.